Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

Contributed by: GlobeNewswire

Tags

Ascendis

More Like This

PR Newswire associated0

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

PR Newswire associated0

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Ascensia Diabetes Care has announced a strategic partnership with health technology startup Sava Technologies to support the introduction and commercialization of its innovative wearable microsensor.

Ascensia Announces Strategic Partnership with Sava for Innovative Microsensor Technology

PR Newswire associated0

Adcendo ApS to Participate in Upcoming September Investor Conferences

PR Newswire associated0

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

PR Newswire associated0

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

PR Newswire associated0

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023